You are currently on the new version of our website. Access the old version .

8 Results Found

  • Review
  • Open Access
3 Citations
6,698 Views
11 Pages

Since the publication of “Application Guideline for Western Traditional Herbal Medicines as OTC Drugs” in 2007, only two European ethnopharmaceuticals, Vitis vinifera L., folium extract (Antistax) and Vitex agnus-castus L., fructus extract (Prefemin)...

  • Review
  • Open Access
19 Citations
23,795 Views
24 Pages

Global Regulatory Challenges for Medical Devices: Impact on Innovation and Market Access

  • Carolina Amaral,
  • Maria Paiva,
  • Ana Rita Rodrigues,
  • Francisco Veiga and
  • Victoria Bell

12 October 2024

Medical devices play a crucial role in human health. These are instruments, machines or even software programs used to diagnose, treat, monitor or prevent health conditions. They are designed to help improve patients’ quality of life and range...

  • Review
  • Open Access
66 Citations
11,174 Views
17 Pages

Several expedited regulatory review projects for innovative drugs and regenerative medical products have been developed in the US, the EU, and Japan. Each regulatory agency has elaborated an original regulatory framework and adopted regulatory projec...

  • Review
  • Open Access
36 Citations
8,271 Views
35 Pages

31 October 2020

Toxicity studies for conventional oral drug formulations are standardized and well documented, as required by the guidelines of administrative agencies such as the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or Europe...

  • Article
  • Open Access
8 Citations
3,953 Views
12 Pages

Glaucoma is the most common cause of blindness, which significantly reduces quality of life. Most glaucoma cases are primary glaucoma; nevertheless, many patients suffer from glaucoma caused by drugs, such as corticosteroids. A comprehensive review o...

  • Article
  • Open Access
10 Citations
3,590 Views
12 Pages

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset

  • Kenta Yamaoka,
  • Masaki Fujiwara,
  • Mayako Uchida,
  • Yoshihiro Uesawa,
  • Nobuyuki Muroi and
  • Tadashi Shimizu

31 August 2022

Poly (ADP-ribose) polymerase (PARP) inhibitors are effective against breast cancer susceptibility gene (BRCA) mutations. Clinical trials have reported hematologic toxicity and gastrointestinal symptoms as class effects of PARP inhibitors. However, in...

  • Review
  • Open Access
23 Citations
8,973 Views
12 Pages

Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature

  • Muhammad Akhtar Abbas Khan,
  • Saima Hamid and
  • Zaheer-Ud-Din Babar

6 January 2023

The world bank has classified 80 economies based on their Gross National Income (GNI) per capita as High-Income. European Medicines Agency (EMA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA) are the major...

  • Article
  • Open Access
1 Citations
1,168 Views
14 Pages

Objective: Current good manufacturing practice (cGMP) guidance for positron emission tomography (PET) drugs has been established in Europe and the United States. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) approved the use of radi...